Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Virology. 2014 Nov 27;475:88–95. doi: 10.1016/j.virol.2014.11.008

An MHC class I immune evasion gene of Marek’s Disease Virus

Cari Hearn a, Likit Preeyanon b, Henry D Hunt b,c, Ian A York b,1,
PMCID: PMC4280340  NIHMSID: NIHMS642731  PMID: 25462349

Abstract

Marek’s Disease Virus (MDV) is a widespread α-herpesvirus of chickens that causes T cell tumors. Acute, but not latent, MDV infection has previously been shown to lead to downregulation of cell-surface MHC class I (Virology 282:198–205 (2001)), but the gene(s) involved have not been identified. Here we demonstrate that an MDV gene, MDV012, is capable of reducing surface expression of MHC class I on chicken cells. Co-expression of an MHC class I-binding peptide targeted to the endoplasmic reticulum (bypassing the requirement for the TAP peptide transporter) partially rescued MHC class I expression in the presence of MDV012, suggesting that MDV012 is a TAP-blocking MHC class I immune evasion protein. This is the first unique non-mammalian MHC class I immune evasion gene identified, and suggests that α-herpesviruses have conserved this function for at least 100 million years.

Keywords: Marek’s disease virus, major histocompatibility complex class I, immune evasion

Introduction

The immune response to viral infection usually eliminates infection and protects against subsequent infection. However, a number of viruses are able to establish long-term infections in spite of the immune response. In particular, members of the herpesvirus family are able to establish latent infections and reactivate in spite of a functional immune response. The mechanisms underlying this ability are not well understood.

Another general feature of herpesviruses is their ability to block the class I major histocompatibility complex (MHC class I) antigen presentation pathway. MHC class I is expressed on the surface of almost all nucleated cells, and consists of a trimolecular complex composed of the highly polymorphic MHC class I heavy chain, β2-microglobulin (β2-m), and a small peptide, usually 8–10 amino acids long. These peptides are generated by proteolysis in the cytosol, mainly by the proteasome (reviewed in [Rock, et al., 2004; Shastri, et al., 2002]), and a small fraction of cytosolic peptides are translocated into the endoplasmic reticulum (ER) lumen by the transporter associated with antigen presentation (TAP). Newly synthesized heavy chain and β2-m assemble together to form a dimer, a process that is facilitated by chaperones such as BiP, calnexin, and calreticulin (Rufer, et al., 2007; reviewed in Hulpke, et al., 2013). After a peptide is loaded onto this dimer, the mature MHC class I complex is allowed to exit the ER and reach the cell surface. If the peptide is derived from a non-self protein, CD8+ cytotoxic T lymphocytes (CTL), an important component of the antiviral immune response, can recognize the MHC class I complex, and respond by lysing the infected cell as well as releasing cytokines that confer an antiviral state on local cells.

Since the first identification of a herpesvirus MHC class I immune evasion gene in 1994 (York, et al., 1994), genes that interfere with MHC class I have been described in at least a dozen other α-, β-, and γ-herpesviruses that infect humans, non-human primates, mice, cattle, horses, deer, and cats (Fruh, et al., 2002; Hudson, et al., 2001; Fruh, et al., 1999; Hislop, et al., 2007; Kleijnen, et al., 1997; Koppers-Lalic, et al., 2008; Powers et al., 2008; Powers and Fruh, 2008; Verweij, et al., 2011). As well, some members of several other viral families, including poxviruses, adenoviruses, and lentiviruses, also have MHC class I immune evasion genes.

Marek’s Disease Virus (MDV) is a ubiquitous α-herpesvirus of chickens that causes Tcell lymphomas in infected birds (reviewed in Jarosinski, et al., 2006). First identified as a disease in 1907 (Marek, 1907), the virus was identified in 1967 (Churchill and Biggs, 1967), and a vaccine was first made available in 1970. However (as with several vaccines against herpesviruses) the vaccine prevents clinical symptoms, but does not prevent infection or transmission of the virus. Probably because of selection for increased transmission in the face of widespread non-sterilizing vaccination, MDV strains have continually increased in virulence; the original vaccine has twice had to be replaced by more effective vaccines (Gimeno, 2008; Nair, 2005). Selective pressures, including vaccination, early cohort removal, and host genetic selection (Gimeno, 2008; Nair, 2005; Atkins, et al., 2013; Hunt and Dunn, 2013), may continue to drive increases in MDV virulence in the future; and new vaccines will probably be required to handle resulting outbreaks (Gimeno, 2008; Nair, 2005).

MDV has been shown to reduce MHC class I surface expression in the acute, but not the latent, phase of infection (Hunt, et al., 2001; Levy, et al., 2003). Although the UL49.5 gene of MDV was shown to reduce expression of MHC class I expression in chicken cells, this gene was found to be only partially responsible for the MHC class I inhibition seen (Jarosinski, et al., 2010), and additional responsible gene(s) have not yet been identified. Homologues of UL49.5 are conserved throughout the herpesvirus lineage, and have been shown to have MHC class I evasion activity in several, though not all, members of the Varicellovirus genus (Koppers-Lalic, et al., 2005; Koppers-Lalic, et al., 2008; Verweij, et. al., 2011) and MDV (Jarosinski, et al., 2010). The UL49.5 genes of Varicelloviruses have been shown to function through inhibition of TAP by several mechanisms (Koppers-Lalic, et al., 2008), while the mechanism of UL49.5 evasion of MHC class I in MDV is not yet known.

Here we identify an additional MDV gene that prevents MHC class I expression, and demonstrate that the gene prevents transport of cytosolic peptides to the ER but does not inhibit peptide loading in the ER. This gene appears to be unique to the nonmammalian mardivirus clade, and, along with the identification of UL49.5, suggests that MHC class I immune evasion has been functionally preserved in the α-herpesviruses for at least 100 million years.

Methods and Materials

Plasmids and cloning

We identified 10 MDV genes that are conserved between MDV strains and whose function has not been determined, and used PCR to clone these genes from a bacterial artificial chromosome (BAC) containing the genome of the virulent Md11 strain of MDV (Niikura, et al., 2006). The MDV genes are listed in Table 1; the primers used to amplify each of the genes are listed in Table 2. Genes were amplified using high-fidelity polymerases (either Pfx [Invitrogen, Carlsbad, CA] or Phusion polymerase [Finnzymes, Woburn, MA]) and subcloned into pTracerCMV2 (Invitrogen). Each gene was completely sequenced to confirm that no point mutations were introduced during the cloning process.

Table 1.

Marek’s Disease Virus candidate genes for MHC class I immune evasion.

Gene Protein / Comment
MDV002 Arg-rich protein, RLORF1
MDV009 Hypothetical protein
MDV012 MDV011 and MDV012 are spliced to form MDV012
MDV049.5 Transmembrane protein / Immune evasion in some varicelloviruses
MDV069 Hypothetical protein LORF4
MDV082 Hypothetical protein
MDV085 Hypothetical protein
MDV086 Cytoplasmic protein
MDV087 Related to G. gallus hypothetical protein LOC422090
MDV093 Hypothetical protein SORF4

Marek’s Disease Virus genes that are conserved between virus strains, and for which no function has been proposed, were cloned for assessment of MHC class I immune evasion

Table 2.

Primers used to amplify Marek’s Disease Virus genes from the MDV genome.

Gene Primer 1 Primer 2
MDV002 gcgaattc GTGCACGGGGATCTGC gctctaga TATTGATGGTACTGTCGCCG
MDV009 cggggtacc GTGGCAAACCACGACTACCT gctctaga CATATCCGATTGGCTCACCT
MDV012g gcgaattc CGGTGCTTTGTACTTCCTACG gctctaga TGGATTTGCAATCACACAACA
MDV049.5 Provided by K. Osterreider, Cornell University
MDV069 gcgaattc GCCACCCTTAAGTCTTCGTG gctctaga TCTCAGATATGTCTTGTTAAAGTGTGG
MDV082 gcgaattc CGGAAGCGATACTACTGCTG gctctaga CGTAACATTCGAACAAGTACCAAG
MDV085 gcgaattc GCTTAACCGGCAGTACAGGA gctctaga CGATGTGCTGAAAGTCGAAA
MDV086 cggggtacc GGGCATGTCTGATCCTTCA gctctaga TGGGCTACAATTCCCTTTTG
MDV087 cggggtacc AGGCCATATCAGCTTTCACG gctctaga TCACGTGATATCCGGTCAAA
MDV093 gcgaattc CGCGTTACCTGCAATAATGA gctctaga TCATATCCCGACGATGAAAA
MDV012s CTCAAGCTTCGCCACCACCATGACTAGCGAG
AGAGCTCTTACTCTCGCGCCTGGTAAAGTTT
CGACGGCAGATATTTATGAAGCCGATTTCAG
TTTCCGTCGTGAATTTGTACGCCAAATTTTA
CAACGATTATTCCCAAGGACCTT
CTCAAGCTTCGCCACCACCATGACTAGCGAGAGAGCT
CTTACTCTCGCGCCTGGTAAAGTTTCGACGGCAGATA
TTTATGAAGCCGATTTCAGTTTCCGTCGTGAATTTGT
ACGCCAAATTTTACAACGATTATTCCCAAGGACCTT

To confirm the spliced nature of the MDV012 gene, total RNA was isolated from chick embryo fibroblasts infected with the Md5 strain of MDV using the RNeasy kit (Qiagen, Valencia, CA). The RNA was subjected to reverse transcriptase PCR using the OneStep RT-PCR kit (Qiagen) with the following primers: 5’- ATGACTAGCGAGAGAGCTCTTACTC-3’ and 5‘-TTCATCATCTGAACTCGACAT-3’, and the product was completely sequenced.

The spliced MDV012-EGFP fusion construct (MDV012s) was made by PCR amplification of Md5 DNA. The 5’ primer comprises the entire first MDV012 exon (109 bps) and the first 19 base pairs of the second exon. This primer also incorporates a Hind III site at its 5’ end to facilitate cloning. The 3’ primer incorporates a BamHI site, allowing cloning of the PCR product into pEGFP-N1 (Clontech, Mountain View, CA), to construct a GFP fusion protein. Primer sequences are shown in Table 1. The resulting MDV012-pEGFP was sequenced to confirm that no errors were introduced during construction.

To construct plasmids expressing cytosolic and ER-targeted B21-binding peptide REVDEQLLSV (Koch, et al., 2007), we annealed oligonucleotides and cloned them into a ubiquitin fusion vector, pUG1 (York, et al., 2006), or into a signal-sequence containing vector (York, et al., 2002), as previously described (York, et al., 2006; York, et al., 2002). The oligonucleotides are listed in Table 3.

Table 3.

Oligonucleotides used to construct peptide-expression plasmids

Oligo name Description Sequence
pUG-R10VF Ubiquitin fusion (cytosolic) REVDEQLLSV AGGGAGGTGG ACGAGCAGCT GCTGAGCGTG TGA CTGCAG
pUG-R10VR GATC CTGCAGTCAC ACGCTCAGCA GCTGCTCGTC CACCTCCCT
ssAR10VF signal sequence A-REVDEQLLSV aactgcagcgct GCC AGGGAGGTGG ACGAGCAGCT GCTGAGCGTG tag ttctagagc
ssAR10VR gctctagaa cta CACGCTCAGC AGCTGCTCGT CCACCTCCCT GGC agcgctgcagtt

Influenza hemagglutinin (HA) was subcloned into pTracerCMV2 (pTracerCMV2-HA). A single-chain MHC class I dimer comprising mouse β2-mb and the mouse MHC class I allele H-2Kb, joined by a flexible linker, and cloned into pTracerCMV2 (pTracerCMV2-β2-mb-SC-Kb), has been previously described (York, et al., 2005). Plasmids expressing SIINFEKL (the H-2Kb-restricted immunodominant peptide from ovalbumin) as cytosolic ubiquitin fusion proteins (pUG-S8L) or targeted to the ER (ss-AS8L) have been previously described (York, et al., 2006; Hearn, et al., 2009). MDV UL49.5 cloned into pcDNA3 (Invitrogen) was kindly provided by K. Osterreider (Cornell University) and has been previously described (Jarosinski, et al., 2010).

Cell lines and transfection

DF1 cells (chicken fibroblasts, B21 haplotype [Himly, et al., 1998]) were provided by D. Foster (University of Minnesota). LMH (chicken hepatocellular carcinoma cells, unknown haplotype [Kawaguchi, et al., 1987]) was provided by Marcia Miller (Beckman Research Institute of City of Hope, Duarte, CA). Transfections were performed using TransIT LT1 (Mirus, Madison, WI) according to the manufacturer’s instructions.

Antibodies and flow cytometry

Two days after transfection, cells were trypsinized and stained with the following antibodies: C6B12 (anti-chicken MHC class I [Shamansky, et al., 1988], obtained from The Developmental Studies Hybridoma Bank, Iowa City, Iowa); chicken antiserum specific for major or minor B21 (Fulton, et al., 2001); anti-H2-Kb (B8.24.3 [Kohler, et al., 1981]); or anti-HA (H36.5-4.2; [Caton, et al., 1982]). Cells were washed in PBS, and counter-stained with secondary antibodies. Cy5-conjugated second antibodies to mouse or chicken antibodies were purchased from Jackson Immunoresearch (West Grove, PA). Flow cytometry was performed on a BD LSRII or BD FACS Vantage (Becton Dickinson), live cell populations were identified based on forward- and side-scatter characteristics, and transfected cells were identified by gating on GFP-positive cells.

Results

MDV012 reduces surface MHC class I on chicken cells

We transfected chicken DF1 and LMH cells with each of ten cloned MDV genes, and stained cell-surface MHC class I two days after transfection, gating on GFP-positive cells to limit analysis to transfected cells. Most of the genes did not alter MHC class I surface expression significantly (Figure 1A). UL49.5 is an MHC class I immune evasion gene in several, but not all, α-herpesviruses, and has been shown to moderately down-regulate MHC class I on chicken OU2 cells (Jarosinski, et al., 2010) in one report but had no effect in LMH cells or human MJS cells in another report (Verweij, et al., 2011). In our experiments MDV UL49.5 did not consistently reduce MHC class I expression on DF1 (Figure 1A) or LMH cells (data not shown). MDV087 consistently, but only slightly, reduced surface MHC class I on DF1 cells (Figure 1A) but had no consistent effect in LMH cells (data not shown). In contrast, the viral gene MDV012 significantly reduced MHC class I surface expression on DF1 cells (Figure 1A).

Figure 1. MDV012 reduces cell-surface MHC class I.

Figure 1

(A) DF1 cells were transfected with MDV genes as indicated, cloned into pEGFP-N1 (MDV012s) or pTracerCMV2 (all other genes). Two days after transfection the cells were stained for major MHC class I isoform, and transfected cells (GFP positive) were analyzed by flow cytometry. Data are shown as mean fluorescence intensity as a percent of cells transfected with empty vector alone (average of at least three experiments +/− standard deviation). Samples in which the 95% confidence interval does not overlap 100% are indicated with an asterisk (*). (B–D) DF1 (B, C) or LMH (D) chicken cells were transfected with empty vector (thin trace) or with MDV012s (thick trace) and stained for chicken MHC class I using (B) chicken antiserum specific for the major allele of B21, (C) chicken antiserum specific for the minor allele of B21, or (D) a monoclonal antibody specific for chicken MHC class I. Shaded trace: Irrelevant antibody (background staining). Each experiment is representative of at least three replicates.

In the MDV genome, MDV012 is predicted to consist of two exons separated by an 83-bp intron (with the 5’ exon being termed “MDV011” in some annotations), and our original clone of MDV012 from the BAC-encoded MDV genome included the intron (genomic MDV012; “MDV012g”). To confirm that MDV012 gene is spliced as predicted, RT-PCR was performed on total RNA from chick embryo fibroblasts infected with the Md5 strain of MDV, using primers from exon 1 and exon 2. The Md5 version of MDV012 and the surrounding regions are identical to the Md11 version. A single strong PCR product resulted which comprised exon 1 and exon 2 with the intron removed (data not shown), as predicted from the genomic sequence. We cloned this spliced version of MDV012 (MDV012s), fused to GFP at the C-terminus. Expression of this spliced MDV012s fusion construct had an even more dramatic effect on surface expression of MHC class I than did expression of MDV012g (Figure 1A).

Chicken MHC class I genes, unlike most mammalian MHC class I, includes only two isoforms and are closely linked to the TAP genes (Kaufman, et al., 1999). Of the two isoforms of MHC class I, one is expressed more efficiently (major isoform) (Kaufman and Salomonsen, 1997). The reason for this differential expression is unknown, but the minor isoform may act as an NK cell ligand (Ewald and Livant, 2004; O’Neill, et al., 2009; Zhang, et al., 2012). We tested the effect of MDV012 on expression of the major and minor isoform of B21 in DF1 cells, using chicken sera specific for each isoform. The spliced version of MDV012 reduced expression of both isoforms to similar extents (Figure 1B, C). Unspliced MDV012g did not have a consistent effect on the minor isoform of B21 (data not shown), and the originally noted effect in DF1 cells stained for the major isoform of B21 was mild and somewhat variable in repeated experiments; thus splicing might be important for gene function, although the difference in vectors used preclude a direct comparison between spliced and unspliced forms of this gene. MDV012s efficiently reduced cell-surface levels of MHC class I on LMH cells (Figure 1D).

MDV012 inhibition of MHC class I expression is specific

Cells transiently transfected with MDV012 showed no obvious signs of toxicity. To test whether the effect on MHC class I expression is specific, we co-transfected DF1 cells with MDV012s (or with empty vector as a control) and either influenza HA, or mouse H-2Kb expressed as a single chain fused with β2-m (“SC-Kb”). Mammalian MHC class I heavy chain expressed in chicken cells is expressed very inefficiently. However, in preliminary experiments we determined that single-chain fusions of mammalian MHC class I heavy chains fused to mammalian β2-m are expressed effectively in chicken cells. Presumably the reason for poor expression of mammalian MHC class I in chicken cells is that chicken β2-m, which is only ~45% identical to human and mouse β2-m, does not bind efficiently to mammalian heavy chains. Providing an appropriate binding partner in the form of mammalian β2-m allows dimer formation and permits surface expression. MDV012 reduced expression of endogenous chicken MHC, as expected (Figure 2A). MDV012 also reduced expression of co-transfected SC-Kb (Figure 2B). However, surface expression of HA was not reduced by co-expression of MDV012 (Figure 2C). This observation shows that MDV012 does not non-specifically block protein expression or cell-surface transport of glycoproteins. As well, since MDV012 did block expression of mouse MHC class I as well as endogenous chicken MHC class I, the effect of MDV012 on surface expression of MHC class I must not be dependent on chicken-specific MHC class I sequence or conformation.

Figure 2. MDV012 reduces expression of H-2Kb, but not of influenza HA, in chicken cells.

Figure 2

DF1 cells were transfected with empty vector (thin traces) or with MDV012s (thick traces) and co-transfected with (B) single-chain β2-m/H-2Kb fusion protein (SC-Kb) or (C) with influenza hemagglutinin (HA). After two days, cells were stained with (A) anti-major B21 chicken antiserum, (B) anti-H-2Kb (B8.24.3), or (C) anti- HA (H36.5-4.2). Cells were gated on GFP to limit analysis to transfected cells. Shaded traces: Irrelevant antibodies (background staining). Each experiment is representative of at least three replicates.

MHC class I-binding peptide rescues expression of MHC class I

The TAP peptide transporter is a bottleneck in the antigen processing pathway and is probably not required for cellular processes other than MHC class I antigen presentation. Accordingly, many mammalian herpesviruses target in TAP for evading MHC class I. To test whether chicken TAP is a potential target for MDV012, we used a peptide that has been shown to bind to the chicken MHC class I B21 allele, REVDEQLLSV (R10V) (Koch, et al., 2007). We targeted the peptide to the ER lumen with a signal sequence, or to the cytosol by expressing the peptide as a ubiquitin fusion protein. Peptides fused to the C-terminus of ubiquitin are rapidly cleaved by ubiquitin C-terminal hydrolases, releasing ubiquitin and the C-terminal sequence as a cytosolic peptide with a defined Nterminus (Bachmair, et al., 1986; York, et al., 2006). R10V targeted to the ER by a signal sequence (and thereby bypassing the requirement for TAP) restored most of the MHC class I surface expression on DF1 cells (which express B21) (Figure 3A), but did not affect surface expression of MHC class I in LMH cells (whose MHC class I type is not B21, and which are therefore not expected to bind R10V) (Figure 3B). In contrast, cytosolic expression of R10V did not rescue surface MHC class I expression in DF1 or LMH cells (Figure 3A, B). These experiments suggest that MDV012 acts by blocking chicken TAP. Importantly, the rescue of surface MHC class I expression in the presence of ss-R10V further demonstrates that MDV012 does not prevent transcription, translation, or surface expression of MHC class I, but reduces surface expression by preventing newly-formed chicken MHC class I in the ER from having access to peptide.

Figure 3. B21-binding peptide (R10V) targeted to the ER, but not the cytosol, rescues cell-surface expression of B21 in the presence of MDV012.

Figure 3

(A) DF1 cells (B21 +) or LMH cells (B21 -) were transfected with MDV012s (dark bars) or with empty vector as a control (open bars), and co-transfected with either empty vector (“Ctrl”), with the peptide R10V as a cytosolic ubiquitin fusion protein (“R10V”, cytosolic), or with an ER-targeted version of R10V (“ss-R10V”). Two days later, the cells were stained with anti-major B21 chicken serum (A) or with anti-chicken MHC class I (B) and analyzed by flow cytometry.

MDV012 orthologues are present in the Mardivirus clade

In MDV, MDV012 is a 489-amino acid protein that is encoded by two exons separated by an 83-bp intron. Related proteins are present in other members of the Mardivirus clade: Gallid Herpesvirus 3 (GaHV-3; also known as Marek’s Disease Virus Type 2), Meleagrid herpesvirus 1 (MeHV-1; also known as herpesvirus of turkeys), and Duck Enteritis Virus (DEV) (Figure 4). The MDV (GenBank: NC_002229) and MeHV-1 (GenBank: NC_002641) genes are annotated as spliced genes in at least some of the genomic sequences. Although the GaHV-3 gene is not annotated as spliced in the genomic sequence (GenBank: NC_002577), analysis with splicing prediction programs (Hebsgaard, et al., 1996) indicates that this gene is also very likely to be spliced, extending the similarity with GaHV-1 and MeHV-1 sequences. The DEV (GenBank: NC_013036) gene LORF3 has similarity to the second exon of MDV012. However, we did not identify an obvious upstream exon for this gene. Most of the similarity between these four proteins is in the N-terminus, with the C-terminal half of the proteins being quite dissimilar. Infectious Laryngotracheitis virus (ILTV; also known as GaHV-1) and Psittacid herpesvirus 1 (PsHV-1), members of the Iltovirus clade of avian herpesviruses, do not have obvious orthologues of MDV012.

Figure 4. MDV012 orthologues.

Figure 4

MDV012-related proteins of Marek’s Disease Virus (MDV), gallid herpesvirus 3 (GaHV3), Meleagrid herpesvirus 1 (MeHV1), and Duck enteritis virus (DEV). Regions of identity are boxed. The junction between exons 1 and 2 in MDV, GaHV3, and DEV is indicated with an arrow.

Discussion

Here we demonstrate that Marek’s Disease Virus, an α3-herpesvirus of chickens that diverged from mammalian herpesviruses at least 100 million years ago (McGeoch, et al., 2006), encodes a gene (MDV012) that specifically blocks surface expression of MHC class I. The ability to block surface expression of MHC class I has been previously shown for MDV (Hunt, et al., 2001; Levy, et al., 2003), and while one partially responsible gene has been identified, another gene(s) is expected to contribute significantly to this function (Jarosinski, et al., 2010).

Our experiments suggest that MDV012 blocks antigen processing at the level of the TAP peptide transporter, a common target of viral MHC class I immune evasion genes. In particular, the MDV012-imposed block on surface expression of MHC class I proteins is overcome when a peptide epitope binding the chicken MHC class I is delivered into the ER, but not when the peptide is delivered to the cytosol. This indicates that MDV012 does not post-translationally destroy MHC class I or prevent its transcription, translation, or trafficking, but rather affects peptide availability within the ER lumen.

Also consistent with a TAP blockade is the observation that MDV012 reduces surface expression of both the major and minor MHC class I isoforms. The function of minor isoforms of MHC class I is not well understood. One possibility is that the minor isoform of MHC class I acts as an inhibitory NK ligand (Ewald and Livant, 2004; O’Neill, et al., 2009; Zhang, et al., 2012); if so, the reduction in the minor isoform by MDV012 may render cells susceptible to NK recognition and lysis, unless, like many other herpesviruses, MDV also has additional genes which block NK recognition of infected cells.

MDV012 is a member of a small family of proteins with unknown functions (the “DUF1509” superfamily) that are found in several avian herpesviruses of the Mardivirus clade (GaHV-3, DEV, and MeHV-1). It is not yet known if the DUF1509 proteins encoded by these other viruses also have an immune-evasion function, but if so MDV012 may be a part of another small cluster of related immune-evasion genes in closely-related viruses. Aside the members of the Mardiviruses, no proteins related to MDV012 have been identified.

The observation that Marek’s Disease Virus is able to block MHC class I expression suggests that MHC class I immune evasion has been functionally conserved in the α- herpesviruses for at least 100 million years (McGeoch, et al., 2006). Although it remains possible that MHC class I immune evasion was independently invented by α-, β-, and γ-herpesviruses, the widespread presence of MHC class I immune evasion genes in β-, and γ-herpesviruses suggests that the common ancestor of the α-, β-, and γ-herpesviruses, about 400 milllion years ago (McGeoch and Gatherer, 2005), had MHC class I immune evasion genes. Analysis of α4-herpesviruses (e.g. ILTV virus of chickens), which diverged from mammalian α-herpesviruses about 200 million years ago (McGeoch, et al., 2006), and especially of herpesviruses of reptiles and fish (which diverged over 400 million years ago (McGeoch and Gatherer, 2006), prior to the establishment of distinct α, β, and γ lineages) will be necessary to determine how ancient MHC class I immune evasion is.

Marek’s Disease is a major concern for the global poultry industry. MDV strains vary widely in virulence, and new strains have increased in virulence over time. However, the MDV012 gene is identical in very virulent (Md5 strain, GenBank: AF243438.1), virulent (RB-1B, GenBank: EF523390.1, and Md11, GenBank: AY510475.1), mildly virulent (CU-2, GenBank: EU499381.1), and vaccine (CVI988, GenBank: DQ530348.1) strains of MDV, suggesting that MDV012 is unlikely to play a direct role in the differing virulence of different field isolates.

Over 20 billion doses of MD vaccine are given annually, but although the vaccine protects against disease it does not confer sterilizing immunity, leading to concerns that the vaccine itself may be driving increased MDV virulence over time (Gimeno, 2008; Nair, 2005). The presence of MDV012 in the widely-used vaccine strain CV1988 raised the possibility that deleting MDV012 from the virus may attenuate the virus as well as increase its immunogenicity; however, we found that deleting MDV012 from the Md5 strain of MDV by BAC mutagenesis made the virus non-viable in tissue culture, confirming another report that MDV012 is an essential gene for in vitro replication (Chattoo, et al., 2006) and suggesting that it may perform more than one function. A recent report of mild viral attenuation by single-SNP incorporation into non-coding regions of MDV012 without significant loss of in vivo replication suggests that it may be possible to study the function(s) of this gene in vitro and in vivo using small mutations or gene knockdown methods (Hildebrandt, et al., 2014).

Resistance to MDV varies widely between different strains of chickens, and resistance is linked to the B21 haplotype (Briles, et al., 1977; Hutt and Cole, 1947; Longenecker, et al., 1977), likely due at least in part to its broad peptide binding repertoire for MHC class I presentation (Koch, et al., 2007; Sherman, et al., 2008). Chicken MHC class I heavy chains are tightly linked to TAP genes (Shaw, et al., 2007), which are relatively variable between chicken strains (Walker, et al., 2005). Could resistance to MDV also be associated with the relative affinity of MDV012 to different TAP alleles? While MDV012 seems to have a somewhat more marked effect on surface expression of MHC class I in LMH (which are not B21 haplotype) than on DF-1 cells (B21 haplotype), further experiments will be necessary to test whether this is a general effect and if it is relevant to MDV pathogenesis in natural infections.

In general, the function of MHC class I immune evasion genes in viral pathogenesis is poorly understood, mainly because of the lack of suitable animal models. Mouse β- and γ-herpesviruses (MCMV and MHV68, respectively) lacking MHC class I immune evasion functions have been analyzed in their natural hosts (Bennett, et al., 2005; Stevenson, et al., 2002a; Stevenson, et al., 2002b). For MCMV, the lack of MHC class I immune evasion was associated only with increased titers of virus in salivary glands (Lu, et al., 2006), but had only a modest effect on immune responses, viral titers, viral persistence in other tissues, or virulence (Gold, et al., 2004; Krmpotic, et al., 1999; Doom and Hill, 2008). MHV68 lacking MHC class I immune evasion was similar to wildtype virus during acute infection of mice, but was more susceptible to immune clearance during the latent phase (Bennett, et al., 2005; Stevenson, et al., 2002a; Stevenson, et al., 2002b).

Among the α-herpesviruses, the two MHC class I immune evasion genes which have been studied in the natural host are the UL49.5 genes of bovine herpesvirus type 1 (BHV-1) and of MDV. In the case of BHV-1, deleting specific residues in the luminal and cytoplasmic tail regions of UL49.5 allowed abrogation of TAP inhibition without affecting replication in vivo or in vitro (Wei, et al., 2011; Wei, et al., 2012). In calves, BHV-1 lacking class I immune evasion was equally virulent to the wild-type virus, but elicited an earlier adaptive immune response (Wei, et al., 2012). Similarly, deleting the cytoplasmic tail from MDV UL49.5 resulted in a virus with partially reduced immune evasion activity but which retained wild-type replication and virulence in the chicken, although the immune response was not studied in this case (Jarosinski, et al., 2010). These studies indicate that MHC class I immune evasion is not an essential function for replication, and deleting this function might be a useful tool to increase the immunogenicity of live vaccines against α-herpesviral diseases of domestic animals or humans.

Although not studied in vivo in the natural host, the ICP47 gene of the human α- herpesviruses HSV-1 and -2 blocks human TAP in vitro (Hill, et al., 1995), and an ICP47 knockout showed altered neurovirulence in mice (Orr, et al., 2005); however, ICP47 has poor affinity for mouse TAP (Tomazin, et al., 1998), so this model is not necessarily relevant to class I immune evasion. The other human α-herpesvirus, VZV, which interferes with MHC class I maturation and trafficking via the ORF66 protein kinase (Eisfeld, et al., 2007), lacks a suitable animal model of infection. Thus, evidence for the relative importance of this mechanism in α-herpesvirus infection will likely have to be gained from studying animal diseases in their natural hosts. The chicken is a particularly useful model, as it is small, easily housed, available in inbred lines, and well-characterized. Infection of chickens with MDV lacking functional MHC class I evasion by MDV012 may prove useful for understanding the function of MHC class I immune evasion by α-herpesviruses in pathogenesis.

Highlights.

  • A novel gene in MDV down regulates surface MHC class I expression.

  • ER targeted peptide, bypassing TAP, rescues MHC class I from down regulation by this MDV gene.

  • This MDV gene is present in other Mardiviruses, suggesting early conservation of immune evasion.

Acknowledgements

We thank Barbara Christian for excellent technical help, Walter Esselman and Vilma Yuzbasiyan-Gurkan for helpful discussions, Lonnie Milam for technical advice, and Robert Silva for technical advice and critical reading of the manuscript. LP received support from the Royal Thai Government Scholarship. CH received support from the Kenneth H. Eskelund Fund for Avian Health and from the NIH (awards # T32OD011167 [previously RR018411] and T32OD011127).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Atkins KE, Read AF, Savill NJ, Renz KG, Islam AF, Walkden-Brown SW, Woolhouse MEJ. Vaccination and reduced cohort duration can drive virulence evolution: Marek’s disease virus and industrialized agriculture. Evolution. 2013;67:851–860. doi: 10.1111/j.1558-5646.2012.01803.x. [DOI] [PubMed] [Google Scholar]
  • 2.Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986;234:179–186. doi: 10.1126/science.3018930. [DOI] [PubMed] [Google Scholar]
  • 3.Bennett NJ, May JS, Stevenson PG. Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol. 2005;3:e120. doi: 10.1371/journal.pbio.0030120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Briles WE, Stone HA, Cole RK. Marek's disease: effects of B histocompatibility alloalleles in resistant and susceptible chicken lines. Science. 1977;195:193–195. doi: 10.1126/science.831269. [DOI] [PubMed] [Google Scholar]
  • 5.Burgos JS, Serrano-Saiz E, Sastre I, Valdivieso F. ICP47 mediates viral neuroinvasiveness by induction of TAP protein following intravenous inoculation of herpes simplex virus type 1 in mice. J. Neurovirol. 2006;12:420–427. doi: 10.1080/13550280601009546. [DOI] [PubMed] [Google Scholar]
  • 6.Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell. 1982;31:417–427. doi: 10.1016/0092-8674(82)90135-0. [DOI] [PubMed] [Google Scholar]
  • 7.Chattoo JP, Stevens MP, Nair V. Rapid identification of nonessential genes for in vitro replication of Marek's disease virus by random transposon mutagenesis. J. Virol. Methods. 2006;135:288–291. doi: 10.1016/j.jviromet.2006.03.011. [DOI] [PubMed] [Google Scholar]
  • 8.Churchill AE, Biggs PM. Agent of Marek's disease in tissue culture. Nature. 1967;215:528–530. doi: 10.1038/215528a0. [DOI] [PubMed] [Google Scholar]
  • 9.Doom CM, Hill AB. MHC class I immune evasion in MCMV infection. Med. Microbial. Immunol. 2008;197:191–204. doi: 10.1007/s00430-008-0089-y. [DOI] [PubMed] [Google Scholar]
  • 10.Eisfeld AJ, Yee MB, Erazo A, Abendroth A, Kinchington PR. Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and - independent mechanisms. J. Virol. 2007;81:9034–9049. doi: 10.1128/JVI.00711-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ewald SJ, Livant EJ. Distinctive polymorphism of chicken B-FI (major histocompatibility complex class I) molecules. Poult Sci. 2004;83:600–605. doi: 10.1093/ps/83.4.600. [DOI] [PubMed] [Google Scholar]
  • 12.Fruh K, Bartee E, Gouveia K, Mansouri M. Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res. 2002;88:55–69. doi: 10.1016/s0168-1702(02)00120-x. [DOI] [PubMed] [Google Scholar]
  • 13.Fruh K, Gruhler A, Krishna RM, Schoenhals GJ. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol. Rev. 1999;168:157–166. doi: 10.1111/j.1600-065x.1999.tb01290.x. [DOI] [PubMed] [Google Scholar]
  • 14.Fulton JE, Hunt HD, Bacon LD. Chicken major histocompatibility complex class I definition using antisera induced by cloned class I sequences. Poult Sci. 2001;80:1554–1561. doi: 10.1093/ps/80.11.1554. [DOI] [PubMed] [Google Scholar]
  • 15.Gimeno IM. Marek's disease vaccines: a solution for today but a worry for tomorrow? Vaccine. 2008;26(Suppl 3):C31–C41. doi: 10.1016/j.vaccine.2008.04.009. [DOI] [PubMed] [Google Scholar]
  • 16.Gold MC, Munks MW, Wagner M, McMahon CW, Kelly A, Kavanagh DG, Slifka MK, Koszinowski UH, Raulet DH, Hill AB. Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J. Immunol. 2004;172:6944–6953. doi: 10.4049/jimmunol.172.11.6944. [DOI] [PubMed] [Google Scholar]
  • 17.Hearn A, York IA, Rock KL. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J. Immunol. 2009;183:5526–5536. doi: 10.4049/jimmunol.0803663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S. Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res. 1996;24:3439–3452. doi: 10.1093/nar/24.17.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hildebrandt E, Dunn JR, Perumbakkum S, Niikura M, Cheng HH. Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence. J. Virol. 2014;88:6232–6242. doi: 10.1128/JVI.03869-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995;375:411–415. doi: 10.1038/375411a0. [DOI] [PubMed] [Google Scholar]
  • 21.Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK. The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology. 1998;248:295–304. doi: 10.1006/viro.1998.9290. [DOI] [PubMed] [Google Scholar]
  • 22.Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 2007;204:1863–1873. doi: 10.1084/jem.20070256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hudson AW, Howley PM, Ploegh HL. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. J. Virol. 2001;75:12347–12358. doi: 10.1128/JVI.75.24.12347-12358.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hulpke S, Tampe R. The MHC I loading complex: a multitasking machinery in adaptive immunity. Trends Biochem. Sci. 2013;38:412–420. doi: 10.1016/j.tibs.2013.06.003. [DOI] [PubMed] [Google Scholar]
  • 25.Hunt HD, Lupiani B, Miller MM, Gimeno I, Lee LF, Parcells MS. Marek's disease virus down-regulates surface expression of MHC (B Complex) Class I (BF) glycoproteins during active but not latent infection of chicken cells. Virology. 2001;282:198–205. doi: 10.1006/viro.2000.0797. [DOI] [PubMed] [Google Scholar]
  • 26.Hunt HD, Dunn JR. The influence of host genetics on Marek’s disease virus evolution. Avian Diseases. 2013;57:474–482. doi: 10.1637/10315-080212-Reg.1. [DOI] [PubMed] [Google Scholar]
  • 27.Hutt FB, Cole RK. Genetic Control of Lymphomatosis in the Fowl. Science. 1947;106:379–384. doi: 10.1126/science.106.2756.379. [DOI] [PubMed] [Google Scholar]
  • 28.Jarosinski KW, Tischer BK, Trapp S, Osterrieder N. Marek's disease virus: lytic replication, oncogenesis and control. Expert Rev Vaccines. 2006;5:761–772. doi: 10.1586/14760584.5.6.761. [DOI] [PubMed] [Google Scholar]
  • 29.Jarosinski KW, Hunt HD, Osterrieder N. Down-regulation of MHC class I by the Marek’s disease virus (MDV) UL49.5 gene product mildly affects virulence in a haplotype-specific fashion. Virology. 2010;405:457–463. doi: 10.1016/j.virol.2010.06.041. [DOI] [PubMed] [Google Scholar]
  • 30.Jugovic P, Hill AM, Tomazin R, Ploegh H, Johnson DC. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J. Virol. 1998;72:5076–5084. doi: 10.1128/jvi.72.6.5076-5084.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kaufman J, Salomonsen J. The "minimal essential MHC" revisited: both peptide-binding and cell surface expression level of MHC molecules are polymorphisms selected by pathogens in chickens. Hereditas. 1997;127:67–73. doi: 10.1111/j.1601-5223.1997.t01-1-00067.x. [DOI] [PubMed] [Google Scholar]
  • 32.Kaufman J, Milne S, Gobel T, W F, Walker A B, Jacob P J, Auffray C, Zoorob R, Beck S. The chicken B locus is a minimal essential major histocompatibility complex. Nature. 1999;401:923–925. doi: 10.1038/44856. [DOI] [PubMed] [Google Scholar]
  • 33.Kawaguchi T, Nomura K, Hirayama Y, Kitagawa T. Establishment and characterization of a chicken hepatocellular carcinoma cell line, LMH. Cancer Res. 1987;47:4460–4464. [PubMed] [Google Scholar]
  • 34.Kleijnen MF, Huppa JB, Lucin P, Mukherjee S, Farrell H, Campbell AE, Koszinowski UH, Hill AB, Ploegh HL. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 1997;16:685–694. doi: 10.1093/emboj/16.4.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Koch M, Camp S, Collen T, Avila D, Salomonsen J, Wallny H-J, van H, Andrew, Hunt L, Jacob P J, Johnston F, Marston A D, Shaw I, Dunbar P, Cerundolo Rod V, Yvonne Jones E, Kaufman J. Structures of an MHC Class I Molecule from B21 Chickens Illustrate Promiscuous Peptide Binding. Immunity. 2007;27:885–899. doi: 10.1016/j.immuni.2007.11.007. [DOI] [PubMed] [Google Scholar]
  • 36.Kohler G, Fischer-Lindahl K, Heusser C. Characterization of a monoclonal anti-H-2Kb antibody. Immune Syst. 1981;2:202. [Google Scholar]
  • 37.Koppers-Lalic D, Reits EA, Ressing ME, Lipinska AD, Abele R, Koch J, Marcondes Rezende M, Admiraal P, van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FA, Tampe R, Neefjes J, Wiertz EJ. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc. Natl. Acad. Sci. U S A. 2005;102:5144–5149. doi: 10.1073/pnas.0501463102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Koppers-Lalic D, Verweij MC, Lipinska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Rezende MM, Daus F, Bienkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampe R, Neefjes JJ, Chowdhury SI, Ressing ME, Rijsewijk FA, Wiertz EJ. Varicellovirus UL49.5 Proteins Differentially Affect the Function of the Transporter Associated with Antigen Processing, TAP. PLoS Pathog. 2008;4:e1000080. doi: 10.1371/journal.ppat.1000080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Krmpotic A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski H U. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med. 1999;190:1285–1296. doi: 10.1084/jem.190.9.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Levy AM, Davidson I, Burgess SC, Dan Heller E. Major histocompatibility complex class I is downregulated in Marek's disease virus infected chicken embryo fibroblasts and corrected by chicken interferon. Comp Immunol Microbiol Infect Dis. 2003;26:189–198. doi: 10.1016/s0147-9571(02)00055-3. [DOI] [PubMed] [Google Scholar]
  • 41.Longenecker BM, Pazderka F, Gavora JS, Spencer JL, Stephens EA, Witter RL, Ruth RF. Role of the major histocompatibility complex in resistance to Marek's disease: restriction of the growth of JMV-MD tumor cells in genetically resistant birds. Adv. Exp. Med. Biol. 1977;88:287–298. doi: 10.1007/978-1-4613-4169-7_27. [DOI] [PubMed] [Google Scholar]
  • 42.Lu X, Pinto AK, Kelly AM, Cho KS, Hill AB. Murine cytomegalovirus interference with antigen presentation contributes to the inability of CD8 T cells to control virus in the salivary gland. J. Virol. 2006;80:4200–4202. doi: 10.1128/JVI.80.8.4200-4202.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Marek J. Multiple Nervenentzündung (Polyneuritis) bei Hühnern. Deutsche Tierärztliche Wochenschrift. 1907;15:417–421. [Google Scholar]
  • 44.McGeoch DJ, Gatherer D. Integrating reptilian herpesviruses into the family herpesviridae. J. Virol. 2005;79:725–731. doi: 10.1128/JVI.79.2.725-731.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpesvirus genomics and evolution. Virus Research. 2006;117:90–104. doi: 10.1016/j.virusres.2006.01.002. [DOI] [PubMed] [Google Scholar]
  • 46.Nair V. Evolution of Marek's disease -- a paradigm for incessant race between the pathogen and the host. Vet J. 2005;170:175–183. doi: 10.1016/j.tvjl.2004.05.009. [DOI] [PubMed] [Google Scholar]
  • 47.Niikura M, Dodgson J, Cheng H. Direct evidence of host genome acquisition by the alphaherpesvirus Marek's disease virus. Arch Virol. 2006;151:537–549. doi: 10.1007/s00705-005-0633-7. [DOI] [PubMed] [Google Scholar]
  • 48.O'Neill AM, Livant EJ, Ewald SJ. The chicken BF1 (classical MHC class I) gene shows evidence of selection for diversity in expression and in promoter and signal peptide regions. Immunogenetics. 2009;61:289–302. doi: 10.1007/s00251-008-0354-7. [DOI] [PubMed] [Google Scholar]
  • 49.Orr MT, Edelmann KH, Vieira J, Corey L, Raulet DH, Wilson CB. Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice. PLoS Pathog. 2005;1:e7. doi: 10.1371/journal.ppat.0010007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 2008;325:333–359. doi: 10.1007/978-3-540-77349-8_19. [DOI] [PubMed] [Google Scholar]
  • 51.Powers CJ, Fruh K. Signal Peptide-Dependent Inhibition of MHC Class I Heavy Chain Translation by Rhesus Cytomegalovirus. PLoS Pathogens PLoS Pathog. 2008;4:e1000150. doi: 10.1371/journal.ppat.1000150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 2004;5:670–677. doi: 10.1038/ni1089. [DOI] [PubMed] [Google Scholar]
  • 53.Rufer E, Leonhardt RM, Knittler MR. Molecular Architecture of the TAP-Associated MHC Class I Peptide-Loading Complex. J. Immunol. 2007;179:5717–5727. doi: 10.4049/jimmunol.179.9.5717. [DOI] [PubMed] [Google Scholar]
  • 54.Shamansky L, Long X, Miller MM. Isolation and characterization of reticulendotheliosis virus transformed bone marrow cells from congenic lines of chickens differing at the MHC. FASEB J. 1988;2:A482. [Google Scholar]
  • 55.Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 2002;20:463–493. doi: 10.1146/annurev.immunol.20.100301.064819. [DOI] [PubMed] [Google Scholar]
  • 56.Shaw I, Powell TJ, Marston DA, Baker K, van Hateren A, Riegert P, Wiles MV, Milne S, Beck S, Kaufman J. Different evolutionary histories of the two classical class I genes BF1 and BF2 illustrate drift and selection within the stable MHC haplotypes of chickens. J. Immunol. 2007;178:5744–5752. doi: 10.4049/jimmunol.178.9.5744. [DOI] [PubMed] [Google Scholar]
  • 57.Sherman MA, Goto RM, Moore RE, Hunt HD, Lee TD, Miller MM. Mass spectral data for 64 eluted peptides and structural modeling define peptide binding preferences for class I alleles in two chicken MHC-B haplotypes associated with opposite responses to Marek's disease. Immunogenetics. 2008;60:527–541. doi: 10.1007/s00251-008-0302-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Stevenson PG, Boname JM, de Lima B, Efstathiou S. A battle for survival: immune control and immune evasion in murine gamma-herpesvirus-68 infection. Microbes Infect. 2002;4:1177–1182. doi: 10.1016/s1286-4579(02)01643-x. [DOI] [PubMed] [Google Scholar]
  • 59.Stevenson PG, May JS, Smith XG, Marques S, Adler H, Koszinowski UH, Simas JP, Efstathiou S. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat. Immunol. 2002;3:733–740. doi: 10.1038/ni818. [DOI] [PubMed] [Google Scholar]
  • 60.Tomazin R, van Schoot NE, Goldsmith K, Jugovic P, Sempe P, Fruh K, Johnson DC. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J. Virol. 1998;72:2560–2563. doi: 10.1128/jvi.72.3.2560-2563.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Verweij MC, Lipińska AD, Koppers-Lalic D, van Leeuwen WF, Cohen JI, Kinchington PR, Messaoudi I, Bieńkowska-Szewczyk K, Ressing ME, Rijsewijk FAM, Wiertz EJHJ. The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus. J. Virol. 2011;85:2351–2363. doi: 10.1128/JVI.01621-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Walker BA, van Hateren A, Milne S, Beck S, Kaufman J. Chicken TAP genes differ from their human orthologues in locus organisation, size, sequence features and polymorphism. Immunogenetics. 2005;57:232–247. doi: 10.1007/s00251-005-0786-2. [DOI] [PubMed] [Google Scholar]
  • 63.Wei H, Wang Y, Chowdhury SI. Bovine herpesvirus type 1 (BHV-1) UL49.5 luminal domain residues 30–32 are critical for MHC-1 down-regulation in virus-infected cells. PLoS ONE. 2011;6:e25742. doi: 10.1371/journal.pone.0025742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Wei H, He J, Paulsen DB, Chowdhury SI. Bovine herpesvirus type 1 (BHV-1) mutant lacking UL49.5 luminal domain residues 30–32 and cytoplasmic tail residues 80–96 induces more rapid onset of virus neutralizing antibody and cellular immune responses in calves than the wild-type strain Cooper. Vet. Immunol. and Immunopathol. 2012;147:223–229. doi: 10.1016/j.vetimm.2012.04.015. [DOI] [PubMed] [Google Scholar]
  • 65.York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J. Immunol. 2006;177:1434–1443. doi: 10.4049/jimmunol.177.3.1434. [DOI] [PubMed] [Google Scholar]
  • 66.York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 2002;3:1177–1184. doi: 10.1038/ni860. [DOI] [PubMed] [Google Scholar]
  • 67.York IA, Grant EP, Dahl AM, Rock KL. A mutant cell with a novel defect in MHC class I quality control. J. Immunol. 2005;174:6839–6846. doi: 10.4049/jimmunol.174.11.6839. [DOI] [PubMed] [Google Scholar]
  • 68.York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell. 1994;77:525–535. doi: 10.1016/0092-8674(94)90215-1. [DOI] [PubMed] [Google Scholar]
  • 69.Zhang L, Katselis GS, Moore RE, Lekpor K, Goto RM, Hunt HD, Lee TD, Miller MM. MHC class I target recognition, immunophenotypes and proteomic profiles of natural killer cells within the spleens of day-14 chick embryos. Dev. Comp. Immunol. 2012;37:446–456. doi: 10.1016/j.dci.2012.03.007. [DOI] [PubMed] [Google Scholar]

RESOURCES